Blood Group Genotyping for Sickle Cell and Thalassaemi

NHS England, Leeds, has completed a procurement process for the service titled "Blood Group Genotyping for Sickle Cell and Thalassaemia". As the buyer, NHS England sought to embed blood group genotyping into routine medical practice, primarily to minimise adverse reactions in patients with rare blood disorders. This contract falls under the "Blood analysis services" category and covers the region of England, United Kingdom, specifically at the postal code LS1 4AP.

The procurement process reached the award stage on 13th May 2025 and the contract runs from 12th May 2025 to 31st March 2026. With a total procurement value of £140,671, this tender was successfully awarded to NHS Blood and Transplant (NHSBT). The procurement method is labelled as 'Other', indicating a specialised approach tailored to the service's specific requirements.

This procurement opportunity presents significant growth potential for businesses specialising in medical and laboratory services, particularly those capable of advancing blood genotyping. Small and medium enterprises (SMEs) as well as voluntary, community, and social enterprises (VCSEs) would find this opportunity fitting due to the tailored requirements and the chance to collaborate with leading healthcare organisations like NHSBT. Engaging in such procurement processes not only provides financial growth but also enhances business credibility and industry standing through association with nationally significant healthcare projects.

Prospective firms engaging in similar opportunities should focus on innovation in medical technology and robust service provision capabilities.